Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1373)	4/11/2001 2:59:00 PM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

JIm, Speaking of new personnel, note one of the new nominees for the MGI Pharma Board of Directors. From the current proxy statement: Philip S. Schein, M.D. 61 President (US), International Network for Cancer Treatment and Research (building infrastructure for cancer management in the developing world) since 1998, and The Schein Group (medical consulting firm) since 1999, and Adjunct Professor of Medicine and Pharmacology, University of Pennsylvania School of Medicine since 1984. He was the founder and former Chairman and Chief Executive Officer of U.S. Bioscience, Inc. (pharmaceuticals) from 1987 to 1999. He previously held appointments as Vice President for Worldwide Clinical Research and Development, SmithKline and French Labs (pharmaceuticals), Scientific Director of the Vincent T. Lombardi Cancer Research Center, President of the American Society of Clinical Oncology and Chairman of the FDA Advisory Committee for Oncologic Drugs. That last item on his list of credentials is particularly interesting. While things are looking increasingly encouraging for Irofulven’s broad range development and ultimate approval, the recent licensing agreement for Palonosetron marketing rights in N.A. is of greater near-term importance. Palonosetron should be on the market in 2003 and, with an extended half-life, will likely have an important differentiation over the other 3 major drugs in a $1BB marketplace. David